Ending Cholera—A Global Roadmap to 2030 operationalises the new global strategy for cholera control at the country level and provides a concrete path toward a world in which cholera is no longer a threat to public health
The Kenya Essential Medicines List 2019 is an indispensable guide to the medicines recommended for the management of common conditions in Kenya. It is primarily directed at health care providers and medicines supply managers in the public and non-public health sectors. It should be used together wit...h the current versions of updated national clinical guidelines for those conditions for which such guidelines exist
more
A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER IN PUBLIC HEALTH OF THE UNIVERSITY OF NAMIBIA
The Leonard Cheshire Disability and Inclusive Development Centre | University College London | 4 Taviton Street | London WC1H OBT | United Kingdom| Principal Investigator: Dr Raymond Lang | Email: r.lang@ucl.ac.uk | Tel: +44 (0)207 679 1519 | Research Commissioned by the Southern African Federation ...of the Disabled’s (SAFOD) |
DFID-funded Research Programme
more
Third Edition: Revised October 2012
This summary brief highlights key messages from the updated World Health Organization’s recommendation on tranexamic acid (TXA) for the treatment of postpartum haemorrhage (PPH), including policy and program implications for translating the TXA recommendation into action at the country level. In 2...012, WHO published recommendations for the prevention and treatment of postpartum haemorrhage, including a recommendation on the use of TXA for treatment of PPH. The 2017 updated WHO Recommendation on TXA is based on new evidence on use of TXA for treatment of PPH. This summary brief is intended for policy-makers, programme managers, educators and providers.
more
Operational Guidelines for the national and district health workers & planners.
These new approaches include use of selective chemotherapy, Rapid Diagnostic Tests (RDTs), Zinc for treatment of cholera in children and complementary use of OCV
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more